Differential Diagnosis of Brain Diseases Using In Vivo Proton Magnetic Resonance Spectroscopy at 3Tesla : A Preliminary Study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The purpose of this study was to evaluate the usefulness of in vivo 3T 1H MRS with short TE for prescreening various brain diseases. Together with ten normal volunteers, 12 brain tumor patients(2 lymphomas, 5 malignant gliomas) and 5(benign meningiomas) and 10 brain ischemic disease patients(6 acute and 4 subacute infarctions) participated. Lymphomas showed increased intensities of Cho and Lac. Likewise, gliomas showed increased Cho and Lac, but with decreased NAA and β•γ-Glx; in higher grade of gliomas, Lac, Cho, mI and Lip predominantly increased with decrease of NAA. Benign meningiomas showed increased Cho, Lac and β•γ-Glx with decrease of NAA. The alanine peak at 1.47 ppm is a neuronal marker for meningiomas. Infarctions showed increased Lac and Lip and decreased NAA, α-Glx and β•γ-Glx where Lac increased with decrease of α-Glx in acute, and Cho, Lac and Lip increased with decrease of NAA in subacute. Elevated Lac and decreased NAA levels were more aggravated in subacute. Clinical application of the 1H MRS with short TE at 3T is able to povide valuable spectral information for prescreening various brain diseases by monitoring the changes of disease-specific cerebral metabolite concentrations in vivo, and consequently, it can be applicable to assessment of differential diagnosis and malignancy as well.
Abstract
The purpose of this study was to evaluate the usefulness of in vivo 3T 1H MRS with short TE for prescreening various brain diseases. Together with ten normal volunteers, 12 brain tumor patients(2 lymphomas, 5 malignant gliomas) and 5(benign meningiomas) and 10 brain ischemic disease patients(6 acute and 4 subacute infarctions) participated. Lymphomas showed increased intensities of Cho and Lac. Likewise, gliomas showed increased Cho and Lac, but with decreased NAA and β•γ-Glx; in higher grade of gliomas, Lac, Cho, mI and Lip predominantly increased with decrease of NAA. Benign meningiomas showed increased Cho, Lac and β•γ-Glx with decrease of NAA. The alanine peak at 1.47 ppm is a neuronal marker for meningiomas. Infarctions showed increased Lac and Lip and decreased NAA, α-Glx and β•γ-Glx where Lac increased with decrease of α-Glx in acute, and Cho, Lac and Lip increased with decrease of NAA in subacute. Elevated Lac and decreased NAA levels were more aggravated in subacute. Clinical application of the 1H MRS with short TE at 3T is able to povide valuable spectral information for prescreening various brain diseases by monitoring the changes of disease-specific cerebral metabolite concentrations in vivo, and consequently, it can be applicable to assessment of differential diagnosis and malignancy as well.
참고문헌 (40)
- Bihan D. L, , Invest Radiol., 27, pp.6~11 (1992)
- Bo-Young Choe, "Analysis of in vitro 2D-COSY on Human Brain Metabolites for Molecular Stereochemistry: The Preliminary Results", Journal of the Korean Magnetic Resonance Society, 12(1), pp.14~25 (2008), 한국자기공명학회
- Damadian R., , Science, 171, pp.1151~1153 (1971)
- Tovi M, , Acta Radiologica Supplementum, 369, pp.161~163 (1986)
- Barker P. B, , Prog Nucl Magn Reson Spectrosc., 49, pp.99~128 (2006)
- Chiang I. C, , Neuroradiology, 46, pp.619~627 (2004)
- Cousins J. P., , Am J Roentgenol., 164, pp.1337~1347 (1995)
- Braunová Z, , Cell Mol Neurobiol, 20, pp.703~715 (2000)
- Laptook A. R, , Pediatr Res., 38, pp.919~925 (1995)
- Weiner M. W, , Invest Radiol., 23, pp.253~261 (1988)
- Howe F. A, , Magn Reson Q., 9, pp.31~59 (1993)
- Sappey-Marinier D, , Magn Reson Med., 26, pp.313~327 (1992)
- Burtscher I. M, , Am J Neuroradiol, 21, pp.84~93 (2000)
- Poptani H., , Am J Neuroradiol, 16, pp.1593~1603 (1995)
- Weybright P, , Am J Roentgenol, 185, pp.1471~1476 (2005)
- 최치봉, "Evaluation of Hydration Effect on Human Skinby 1H MRS at 14.1T", Journal of the Korean Magnetic Resonance Society, 10(1), pp.105~114 (2006), 한국자기공명학회
- Jeong G.. W, , Concepts Magn Resonance, 18A, pp.146~156 (2003)
- Overloop K., , NMR Biomed, 9, pp.315~321 (1996)
- Radda G. K, , Magn Reson Q., 5, pp.122~151 (1989)
- Christiansen P, , Magn Reson Imaging, 11, pp.107~118 (1993)
- Bottomley P. A, , Radiology, 170, pp.1~15 (1989)
- Castillo M, , AJNR Am J Neuroradiol, 17, pp.1~15 (1996)
- Hashimoto K, , BMC Psychiatry, 5, pp.6~10 (2005)
- Gillard J. H, , Am J Neuroradiol, 17, pp.873~886 (1996)
- Barker P. B, , Seminars in Cerebrovascular Diseases and Stroke, 1, pp.331~342 (2001)
- Bartha R, , Magn Reson Med., 44, pp.185~192 (2000)
- Barker P. B, , Magn Reson Med., 45, pp.765~769 (2001)
- Weybright P, , Neuroradiology, 46, pp.541~549 (2004)
- Barker P. B, , Ann Neurol, 49, pp.423~424 (2001)
- Danielsen E. R, "Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases", pp.6~ (1999), Basel MARCEL DEKKER, INC
- Clark J. B, , Developmental Neuroscience, 20, pp.271~276 (1998)
- Ott D, , Radiology, 186, pp.745~772 (1993)
- Kantarci K, , Radiology, 248, pp.210~220 (2008)
- Tien R. D, , Lazeyras F., Am J Roentgenol, 167, pp.201~209 (1996)
- Negendank W. G, , J Neurosurg, 84, pp.449~458 (1996)
- Meyerand M. E, , Am J Neuroradiol, 20, pp.2~3 (1999)
- Kuesel A. C, , NMR Biomed, 7, pp.149~155 (1994)
- Maxwell R. J, , Magn Reson Med., 39, pp.869~877 (1998)
- Michaelis T, , Radiology, 187, pp.219~227 (1993)
- Kwock L., , Technol Cancer Res Treat., 1, pp.17~28 (2002)